Jardiance Pediatric (<12) School and Activity Considerations

FDA Approval Status and Off-Label Use in Children Under 12

Empagliflozin carries a specific pediatric labeling boundary. The FDA updated the Jardiance prescribing information in 2023 to include children aged 10 years and older with type 2 diabetes, based on data from the DINAMO trial [1]. Children under 10 remain outside the approved indication.

For children aged 10 to 11 (technically within the "under 12" pediatric school-age group), the approved adult starting dose of 10 mg once daily applies, with an option to increase to 25 mg if additional glycemic control is needed and the dose is tolerated [1]. No weight-based dosing adjustment is specified in the current label.

Why Some Children Under 10 Receive It Anyway

Pediatric endocrinologists occasionally use empagliflozin off-label in children under 10 when type 2 diabetes or heart failure management options are limited [2]. The American Diabetes Association's 2024 Standards of Care note that SGLT2 inhibitors may be considered in youth with type 2 diabetes when metformin and lifestyle changes are insufficient, acknowledging that trial data in very young children are sparse [3].

Off-label prescribing shifts the burden of monitoring to the prescribing clinician and the family. School staff should request a copy of the prescriber's written management plan before the child's first school day on the medication.

The DINAMO Trial: What the Data Actually Show

The DINAMO trial (NCT03429543) enrolled 158 pediatric patients aged 10 to 17 with type 2 diabetes. At 26 weeks, empagliflozin 10 mg reduced HbA1c by 0.84 percentage points versus placebo (P<0.001) and empagliflozin 25 mg reduced it by 0.93 percentage points [4]. Body weight fell modestly. No participant experienced severe hypoglycemia as a primary event, but two participants met criteria for possible DKA, a signal that informed the updated prescribing information's warnings [4].

Children under 10 were not enrolled in DINAMO. Extrapolating these findings to younger children requires clinical judgment and close follow-up.

Urinary Frequency: Practical School-Day Management

SGLT2 inhibitors work by blocking sodium-glucose cotransporter 2 in the proximal tubule, causing the kidney to excrete roughly 60 to 80 grams of glucose per day in adults [5]. In children, that glycosuria drives osmotic diuresis, meaning more urine volume and more frequent bathroom trips.

How Often Is "More Often"?

In adult SGLT2 inhibitor trials, pollakiuria (frequent urination) is reported in 3 to 5% of participants, but real-world pediatric experience suggests the effect is noticed more acutely by school-age children who are not accustomed to managing medication side effects [6]. A child taking empagliflozin may need to use the restroom every 60 to 90 minutes during a school day, particularly in the first 2 to 4 weeks of treatment.

Building the School Restroom Access Plan

The Section 504 of the Rehabilitation Act (U.S.) and the Individuals with Disabilities Education Act both provide frameworks for unrestricted restroom access for children with chronic medical conditions [7]. A 504 Plan or Individual Health Plan (IHP) should explicitly state:

• Unrestricted bathroom access without requiring teacher permission
• The right to keep a water bottle at the desk
• Accommodation for any testing period to include bathroom breaks without penalty

The school nurse should document these accommodations before the child begins the medication. Waiting until a problem occurs is not an acceptable substitute for advance planning.

Genital and Urinary Tract Infection Risk

Glycosuria raises the local glucose concentration in the genital area, which promotes fungal and bacterial growth. In the EMPA-REG OUTCOME trial (N=7,020 adults), genital mycotic infections occurred in 6.4% of women and 3.1% of men on empagliflozin versus 1.8% and 0.4% on placebo, respectively [8]. Pediatric data are limited, but the mechanism applies equally to children.

Parents and school nurses should watch for perineal itching, redness, or unusual odor. Prompt reporting to the prescribing physician allows early treatment and prevents school absenteeism.

Dehydration and Fluid Management During the School Day

Osmotic diuresis from glycosuria reduces circulating volume. In warm weather, during physical education class, or when a child has a febrile illness, that baseline volume reduction compounds quickly into clinically significant dehydration.

Daily Fluid Targets

The standard pediatric hydration recommendation from the American Academy of Pediatrics is approximately 30 to 40 mL/kg/day for school-age children [9]. A child on empagliflozin should aim for the upper end of that range on regular school days and an additional 150 to 250 mL per 30 minutes of moderate exercise.

Practical steps for the school day include:

• A labeled 500 mL or larger water bottle in the classroom
• A reminder alarm on a watch or phone set for every 45 to 60 minutes
• Oral rehydration solution (not just plain water) available in the nurse's office for post-exercise recovery

Signs of Dehydration the School Nurse Should Recognize

Early signs include dry lips, dark urine, and a resting heart rate elevated more than 15 beats per minute above the child's personal baseline. The school nurse's action plan should specify: if a child on empagliflozin presents with these signs, contact the parent and prescribing physician before sending the child back to class. Intravenous fluids may be required if oral rehydration fails.

The FDA Jardiance prescribing information specifically lists volume depletion as a warning requiring assessment of renal function before initiating therapy and during sick days [1].

Diabetic Ketoacidosis Risk: What School Staff Must Understand

Euglycemic diabetic ketoacidosis is the most serious acute risk associated with SGLT2 inhibitors in school-age children. It is serious because the blood glucose may read normal or only mildly elevated, which means a child can appear "fine" on a glucometer while ketoacidosis is progressing.

Mechanism of Euglycemic DKA

SGLT2 inhibition promotes renal glucose excretion, reducing blood glucose even as the liver upregulates ketogenesis in response to relative insulin deficiency [10]. The result is ketone accumulation without the classic hyperglycemia that typically triggers DKA recognition. In adult post-marketing surveillance, the FDA received reports of 73 cases of DKA in patients using SGLT2 inhibitors between 2013 and 2015, many with blood glucose below 250 mg/dL [10].

Triggers in the School Setting

Three common school-day scenarios raise DKA risk:

• Prolonged fasting (skipping breakfast before an early class, or forgetting a lunch tray)
• Vigorous sustained exercise (cross-country practice, swimming trials, PE double periods)
• An intercurrent illness with vomiting that reduces carbohydrate intake

The Endocrine Society's 2023 clinical practice guideline on SGLT2 inhibitor safety recommends temporarily stopping the drug 24 to 48 hours before planned prolonged exercise or surgery [11]. For a child's school sports day or a marathon PE session, the prescriber should be notified in advance so the dose can be held that morning.

DKA Symptom Recognition Card for School Staff

Every school nurse and classroom teacher who works with a child on empagliflozin should have a laminated card listing DKA symptoms. These include:

• Nausea or vomiting
• Abdominal pain that does not resolve in 30 minutes
• Rapid or labored breathing
• Fruity-smelling breath
• Unusual fatigue or confusion

If any two of these are present, the action is not "wait and see." Call 911, then call the parent. Do not give the next empagliflozin dose.

A 2020 paper in Diabetes Care reported that delay in DKA recognition beyond two hours increased pediatric ICU length of stay by a median of 1.4 days (P<0.05) [12]. Speed matters.

Physical Education and Organized Sports

Exercise lowers blood glucose through insulin-independent glucose uptake in muscle. SGLT2 inhibitors add a second glucose-lowering mechanism. Together, these may increase hypoglycemia risk during sustained aerobic activity, although SGLT2 inhibitor monotherapy carries a lower intrinsic hypoglycemia risk than sulfonylureas [13].

Low-Intensity vs. High-Intensity Activity

Low-intensity activities (walking, casual bike riding, classroom movement breaks) are generally safe with standard empagliflozin dosing and adequate hydration. The glycemic and hemodynamic stress is modest.

High-intensity or prolonged activities require more preparation. In the EMPA-REG OUTCOME trial, patients who exercised more than 150 minutes per week showed greater volume depletion biomarker changes than sedentary patients [8]. A school child in competitive soccer, swimming, or track events is likely engaging in that exercise intensity during practice and meets.

Pre-Exercise Protocol

A reasonable school sports protocol, consistent with ADA 2024 guidance for youth with type 2 diabetes [3], includes:

1. Check blood glucose before practice (target 100 to 200 mg/dL before starting)
2. If blood glucose is below 100 mg/dL, consume 15 grams of fast-acting carbohydrate before activity
3. Carry an additional 15-gram carbohydrate snack during practice
4. Recheck blood glucose 30 minutes into activity and at the end
5. Drink 150 to 250 mL of water or oral rehydration solution every 30 minutes

The coach and school athletic trainer should have a copy of this protocol. The prescribing physician should confirm these thresholds based on the individual child's history.

After-School and Weekend Sports

Empagliflozin is dosed once daily, typically in the morning. Its glucose-lowering effect persists for roughly 24 hours [1]. A child who takes the dose at 7 AM still has active drug on board during a 4 PM soccer game. Post-exercise monitoring should extend for at least two hours after high-intensity activity ends because delayed hypoglycemia is possible.

A case series published in Pediatric Diabetes described three children aged 11 to 13 on SGLT2 inhibitors who developed symptomatic post-exercise hypoglycemia four to six hours after sustained aerobic activity, despite normal blood glucose immediately post-exercise [14]. Late-onset hypoglycemia in this context is a real, not theoretical, concern.

Sick-Day Rules and School Illness Policy

Gastrointestinal illnesses are common in school-age children. Vomiting and diarrhea reduce carbohydrate intake and cause additional fluid loss, both of which amplify the dehydration and DKA risks already present with SGLT2 inhibitor use.

When to Hold the Dose

The "sick-day rule" for SGLT2 inhibitors is widely endorsed by both the ADA and Endocrine Society: hold the drug whenever the child is unable to maintain adequate oral intake or fluids [3][11]. This means:

• Any vomiting episode of more than one occurrence in 24 hours
• Diarrhea with more than three loose stools in 24 hours
• Fever above 38.5°C combined with reduced food intake
• Any situation where the child has eaten less than half of their normal daily calories

School Nurse Action Protocol

If a child on empagliflozin visits the school nurse with nausea, vomiting, or abdominal pain:

1. Do not administer the next empagliflozin dose if it has not yet been taken
2. Test blood glucose and, if available, urine or blood ketones
3. If ketones are moderate or large (urine) or blood ketones exceed 1.0 mmol/L, treat as a potential DKA emergency
4. Contact the parent immediately regardless of blood glucose reading
5. Document the episode in the child's health record

The FDA's SGLT2 inhibitor class labeling requires that prescribers counsel patients and caregivers on sick-day management and ketone monitoring [1]. That counseling must extend to the school nurse.

Setting Up the School Health Plan

A comprehensive Individual Health Plan (IHP) for a child on empagliflozin should cover the following domains, each with specific numeric thresholds rather than vague instructions.

Medication Administration

• Empagliflozin is typically given once daily at home before school; the school nurse usually does not administer it
• If a dose is accidentally double-administered (child takes it at home and again at school), contact the prescribing physician; no emetic treatment is needed, but monitoring for hypotension and increased urination is appropriate
• Never give a missed dose as a late afternoon or evening catch-up, as evening dosing increases nocturnal urination and disrupts sleep

Monitoring Thresholds That Trigger Action

The IHP should list specific blood glucose and ketone values that require nurse action:

• Blood glucose below 70 mg/dL: treat with 15 g carbohydrate, recheck in 15 minutes, call parent
• Blood glucose above 300 mg/dL: call parent, check ketones
• Urine ketones moderate or large, or blood ketones above 1.5 mmol/L: call 911 and parent simultaneously
• Any DKA symptom (see list above) regardless of glucose reading: call 911 first

These thresholds align with the ADA's pediatric hypoglycemia and DKA management guidance published in Diabetes Care [15].

Communication Chain

The IHP should name a primary contact (parent or guardian), a secondary contact (other caregiver), and the prescribing physician's after-hours number. School nurses report that medication-related adverse events in children with diabetes are resolved faster when a direct physician contact is available, versus routing through a general office line [16].

Communicating with Teachers and Coaches

Classroom teachers and coaches are not expected to be pharmacists. They need simple, actionable information in plain language. Three facts suffice for most teachers:

1. This child takes a diabetes medication that makes them urinate more and increases dehydration risk during exercise.
2. If the child complains of stomach pain, unusual tiredness, or difficulty breathing, call the nurse immediately, even if the child looks otherwise normal.
3. Bathroom trips and water bottle access are medical accommodations, not classroom disruptions.

A brief, one-page letter from the prescribing physician, cosigned by the school nurse, carries more authority than a parent explanation alone. The Endocrine Society's patient education resources include template letters for school staff [11].

Renal Considerations in Younger Children

SGLT2 inhibitors depend on functional glomerular filtration for their glucose-lowering mechanism. In children with reduced eGFR, the drug is less effective and the volume depletion risk remains. The current Jardiance prescribing label states that empagliflozin is not recommended when eGFR is below 45 mL/min/1.73m² for glycemic control [1].

Baseline renal function testing (serum creatinine, eGFR, urinalysis) is required before starting, and reassessment is recommended at 3-month and 12-month intervals [1]. If a school-age child has concurrent nephrotic syndrome or recurrent urinary tract infections, the prescriber should reconsider whether SGLT2 inhibitor therapy is appropriate before school enrollment on the drug.